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Metabolic syndrome (MetS) comprises of a group of associated disease conditions. These 
primarily include insulin resistance, dyslipidemia, and high blood pressure. Visceral adiposity 
majorly contributes to the development and pathogenesis of the metabolic syndrome. Most of 
all of these factors contribute to increased cardiovascular risks. MetS is the principal precursor 
for type 2 diabetes mellitus. It raises the potential risk of inflammatory cardiovascular disease 
(CVD) by 2 folds and further causes a 1.5-fold increase in the risk of mortality (Wilson et al., 
1999). Therefore, all the components about MetS pose a considerable risk, especially in the 
pathophysiology of CVD. It is crucial to recognize and treat each contributing factor to reduce 
the risks of CVD. The primary mechanism leading to the development and pathogenesis of 
MetS is chronic inflammation and other contributing inflammatory elements. In this short letter, 
we have summarized notable findings from recent studies that may provide crucial insights 
concerning the underlying inflammatory mechanisms that lead to the development of MetS. 
Moreover, based on such mechanisms, we have identified potential treatment strategies, includ-
ing vitamin D, which could be a promising agent in the long-term management of inflammation 
and its associated conditions in MetS.  
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Visceral adiposity, excessive intake of a high-fat diet, and defect in fat metabolism via over-
stimulation of RAAS and sympathetic system are the major causative factors leading to the 
pathogenesis of insulin resistance. These pathogenic factors further form the common and es-
sential link between inflammation and MetS. Several mechanisms are currently known, that 
show the progression of insulin resistance to chronic inflammation, which further progresses to 
CVD in MetS (Prasad and Quyyumi, 2004). A substance called monocyte chemo-attractant 
protein-1 (MCP-1) is produced and secreted by the adipocytes. Moreover, they also secrete 
other cytokines, namely, TNF-α and IL-6. These substances predominantly cause infiltration of 
macrophages into adipose tissues (Donath and Shoelson, 2011). As a result, these events lead 
to the mediation of downstream pathways namely, IKK and JNK that produce defective hyper-
phosphorylation of IRS-1 resulting in the development of insulin resistance by disturbing the 
PI3K/AKT signaling. Moreover, adipose tissue also regulates Adiponectin, a contributing fac-
tor for insulin resistance, via maintaining the homeostasis of inflammatory and anti-inflamma-
tory cytokine components, IL-6/TNF-α and IL-10 respectively. Furthermore, JNK and IKK ac-
tivation may lead to the upregulation of NF-κB and AP-1 activation. This may result in the 
production of inflammatory cytokines (Fujioka et al., 2004). Also, inflammasomes are medi-
ated by adipose tissue-derived components like free fatty acid, causing the activation of nods 
like receptors that leads to the formation of IL-1b and IL-18. These are products of cleavage 
resulting from the action of caspase-1 of pro–IL-1b and pro–IL-18 (Welty et al., 2016). Exces-
sive high fat diet further triggers the inflammatory cascade and insulin resistance via the ex-
pression of PLA2 -COX/LOX associated synthesis of PGs and LTs respectively. High fat may 
also recruit neutrophil-mediated IL-6 and TNF-α release. Besides, LT's associated chemotactic 
factor (LTB4) release, further upregulates NF-κB mediated inflammatory cytokines (Horrillo 
et al., 2010). Dyslipidemia in MetS leads to high TG and low HDL cholesterol levels, which 
result in the production of ApoB-100/ApoC-III fatty acid content. It is reported that ApoC-III 
plays a imperative role in the progression of inflammation. Furthermore, it is also reported to 
activate the TLR2 signaling pathway in experimental animals, thereby, serving as an inflam-
matory mediator (Gupta et al., 2014). The resulting cascade of events result in the upregulation 
of NF-κB leading to the upregulation of cytokine production. These mechanisms essentially 
cause insulin resistance, atherosclerosis and thrombosis. 
Dietary modifications, weight management, exercise along with lifestyle therapy are the 
key principles outlining the effective management of MetS. However, various pharmacological 
approaches are also available for controlling the co-morbidities. These include anti-diabetic 
drugs like metformin, glucagon-like-peptide 1 (GLP-1) agonists, other oral hypoglycemic 
agents like sodium-glucose co-transporter 2 (SGLT2) inhibitors, inhibitors of dipeptidyl pepti-
dase 4 (DPP4) enzyme, RAAS blockers (ACE inhibitors and AR blockers), hypolipidemic 
agents (Statins and PPAR-α), K+ sparing diuretics (aldosterone antagonists) and omega 3 fatty 
acids (Aguilar-Salinas and Viveros-Ruiz, 2019). Furthermore, these pharmacological interven-
tions have notable disadvantages and do not effectively suppress the risks of disease progres-
sion. Meta-analysis data from 13 major statin trials, over 4 years, have shown a 9 % increase in 
the development of diabetes when compared with placebo (Sattar et al., 2010). 
In this short communication, we have attempted to explore the robust evidence-based effect 
of vitamin D3 (VitD3) / cholecalciferol supplementation on the inflammation cascade and insu-
lin resistance, which may alter the CVD outcomes in patients with MetS. VitD3 deficiency is 
increasingly recognized as a major health problem across the globe. In India alone, the preva-
lence rates of VitD3 deficiency is reported to be as high as 94 % in urban areas. This could be 
essentially due to poor exposure to sunlight and a sedentary lifestyle, mainly confined to their 
homes or workplaces (Vupputuri et al., 2006). There are several studies, conducted across the 
globe, which connect VitD3 deficiency to inflammatory conditions like MetS. A clinical study 
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conducted among 157 Asian Indians revealed that VitD3 deficiency was found in 73.25 % of 
the individuals. These subjects also had prediabetes. A higher insulin resistance score was ob-
served in subjects having lower VitD3 levels (Dutta et al., 2013). A recent 18-month random-
ized control trial published in Nature Scientific Reports, revealed a significant decrease in pa-
rameters namely, fasting blood sugar levels, glycated hemoglobin, and subcutaneous fat with 
VitD3 administration (Bhatt et al., 2020). Moreover, another trial conducted on migrant South 
Asian women, who had insulin resistance revealed valuable data on VitD3 administration. The 
findings revealed that improvement in VitD3 status reduced insulin resistance and increased 
insulin sensitivity (Gupta et al., 2020; von Hurst et al., 2010). VitD3 also regulates the action of 
a key substance called calbindin. Calbindin is a protein that is usually seen in the pancreatic 
cells. Physiologically, it binds to calcium within the cells and regulates insulin secretion through 
cellular depolarization (Kadowaki and Norman, 1984). VitD3 supplementation further normal-
izes and regulates glucose triggered secretion of insulin. It also modulates the generation and 
physiology of cytokines, thereby enhancing β-cell survival (Cade and Norman, 1987; Singh et 
al., 2017). VitD3 in diabetes has also demonstrated enhanced action of insulin, in terms of trans-
porting glucose and reducing the overall levels of cellular inflammation through the regulation 
of IL-6, TNF-α, IL-10, hsCRP. It further maintains the relative levels of IL-6 to IL-10 along 
with NFκB transcriptional activity (De Vita et al., 2014; Pittas et al., 2007). The antihyperten-
sive function of VitD3 is proposed through suppression of the renin-angiotensin pathway with 
its anti-endothelial stiffness effect, followed by secondary hyperparathyroidism prevention. 
However, progressive renal dysfunction in diabetes mellitus (DM) after VitD3 administration 
has resulted in increased intrarenal vascular calcification. This highlights the possible harmful 
effects of long-term supplementation of VitD3 (Almeida et al., 2020; Gupta et al., 2012). How-
ever, lower or insufficient VitD3 in male subjects led to increased levels of triglycerides and a 
decrease in their HDL-C levels. Furthermore, crucial findings from another clinical study 
showed that HDL-C levels were comparatively boosted up in patients who were administered 
with optimal doses of VitD3 (Alkhatatbeh et al., 2019) (Figure 1). 
As the concluding remark, we provide the proof-of-concept for VitD3, which significantly 
acts as a key factor in the suppression of pro-inflammatory elements, thereby improving insulin 
resistance that modifies the consequences of CVD in MetS, and thus should be included in the 
treatment regimen. 
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